医学
蛋白尿
达帕格列嗪
肾脏疾病
肾病综合征
蛋白尿
内科学
疾病
糖尿病
内分泌学
肾
醛固酮
泌尿科
2型糖尿病
作者
Jiaojiao Liu,Jingyi Cui,Xiaoyan Fang,Jing Chen,Weili Yan,Qian Shen,Hong Xu
标识
DOI:10.1016/j.ekir.2021.12.019
摘要
Proteinuria is one of the most important risk factors for chronic kidney disease (CKD) progression. Approximately 5% to 10% of pediatric nephrotic syndrome is resistant to steroids and other immunosuppressants, and up to one-third of them are caused by monogenic disorders. Blockers of the renin-angiotensin-aldosterone system are considered as the basic treatment for proteinuric CKD. However, these agents often cannot achieve sufficient proteinuria reduction. Recently, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated benefits in reducing proteinuria and improving kidney outcomes in patients with proteinuric CKD with and without type 2 diabetes in adults.
科研通智能强力驱动
Strongly Powered by AbleSci AI